Justice Dept Tweaks Crime Victim Feedback Forms Online

2026-19694, Annual Notices on Explosive Materials Storage Facilities to Local Fire Authority

If you store explosives, you now have to tell your local fire department every year and when you stop storing them. This new rule helps keep firefighters and the public safer by making sure they always know where explosives are stored. It starts on October 26, 2026, and you must keep your notices for five years—no extra fees, just more safety!

2026-19693, Implementing the Safe Explosives Act

The Safe Explosives Act final rule affects businesses and people who handle explosives, making reporting and transport rules clearer and simpler. Starting October 26, 2026, license holders must report key personnel changes but no longer need to verify who accepts deliveries for them. These updates cut red tape without adding new costs, keeping everyone safer and smoother in the explosive world.

2026-16981, Application for Relief From Disabilities Imposed by Federal Laws With Respect to the Acquisition, Receipt, Transfer, Shipment, Transportation, or Possession of Firearms

The Department of Justice ("the Department") is implementing criteria to guide determinations for granting relief from disabilities imposed by federal laws with respect to the acquisition, receipt, transfer, shipment, transportation, or possession of firearms. The criteria are designed to ensure that the fundamental right of the people to keep and bear arms is not unduly infringed, that those people granted relief are not likely to act in a manner dangerous to public safety, and that granting such relief would not be contrary to the public interest.

2026-15458, Civil Money Penalty for Actions in Contempt of an Immigration Judge's Proper Exercise of Authority

This notice of proposed rulemaking ("NPRM") would implement a provision of the Immigration and Nationality Act ("INA" or "the Act") that authorizes Immigration Judges, under regulations prescribed by the Attorney General, to sanction by civil money penalty any action (or inaction) in contempt of the proper exercise of their authority by certain individuals. The rule would: define the scope of the contempt authority; provide procedures for contempt findings, penalty determinations, and penalty payment; establish an appellate process; and implement oversight of the use of contempt authority. The rule would also make conforming changes to the grounds for practitioner discipline.

2026-13586, Registering NFA Firearms That Fall Out of Government Contract

If you make special firearms for the U.S. Government and your contract ends, you’ll now have a new way to register those guns even if you missed the usual deadline. This change helps manufacturers avoid penalties and keeps everything clear and fair. Comments on this proposal are open until September 4, 2026, so don’t miss your chance to weigh in!

2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment

Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.

Previous: 2026-03211, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZEVASKYN (Prademagene Zamikeracel)

The FDA just gave a special priority review voucher to Abeona Therapeutics for their rare pediatric disease treatment, ZEVASKYN, approved in April 2025. This voucher speeds up future drug reviews, helping get important medicines to patients faster. It’s a big win for kids with rare diseases and could save time and money in bringing new treatments to market.

Next: 2026-03213, Determination That TOLECTIN DS (Tolmetin Sodium) Capsule, Equivalent to 400 Milligrams Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The FDA has decided that TOLECTIN DS (tolmetin sodium) 400 mg capsules weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back!